Greenwich LifeSciences (NASDAQ:GLSI) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Greenwich LifeSciences (NASDAQ:GLSI) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $38.00 target price on the stock.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $12.01 on Tuesday. Greenwich LifeSciences has a 52 week low of $8.15 and a 52 week high of $21.44. The stock has a fifty day moving average of $12.73 and a 200-day moving average of $13.57. The stock has a market capitalization of $157.93 million, a P/E ratio of -15.01 and a beta of 1.69.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock in a transaction on Friday, January 10th. The shares were purchased at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the acquisition, the chief executive officer now owns 5,552,502 shares in the company, valued at approximately $69,461,800.02. The trade was a 0.05 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders purchased a total of 10,500 shares of company stock valued at $128,459 over the last three months. Company insiders own 51.67% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

A number of institutional investors have recently modified their holdings of GLSI. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences during the third quarter worth about $253,000. State Street Corp grew its position in shares of Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares during the last quarter. Barclays PLC grew its position in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.